To test whether the stress-activated programme in Mettl1-/- cancer cells could alter their sensitivity to chemotherapy in vivo, we administered Docetaxel, commonly used for treating of metastatic castration-resistant prostate cancer (mCRPC) [56], to mice-bearing tumours. This evidence concerns the gene METTL1 and neoplasm.